



Living Cell Technologies Limited Company Announcement

Annual General Meeting held on 28 November 2011 Amended Poll Result

30 November 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), the Company advises an amendment to the poll result in respect of resolution 6 that was announced on 28 November 2011. This amendment has no impact on the outcome of the resolution.

Resolution 6 Ratification of Issue of Ordinary Shares Pursuant to ASX Listing Rule 7.4

"That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 2,767,528 shares, details of which are set out in the explanatory notes to resolution 6 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
36,694,747	22,025,827	10,268,911

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
6,373,632	20,293,249	0	0

– Ends –

For further information: www.lctglobal.com

<p>At the company: Living Cell Technologies Limited Roy Austin, Chairman Tel: +64 9 9134605 Mobile: +64 21 656400 raustin@lctglobal.com</p> <p>Bob Elliott, Medical Director Tel: +64 9 2762690 Mobile: +64 272924177 belliott@lctglobal.com</p>	<p>Media and analyst enquiries: Symbol Strategic Communications Patrick Sinclair/Robert Luttrell Tel: +61 2 8079 2969 Mobile: +61 403 708 431 psinclair@symbolstrategic.com.au</p> <p>Robert Luttrell +61 419 185 652 rluttrell@symbolstrategic.com.au</p>
--	---

About Living Cell Technologies - www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.